Genmab A/S Sponsored ADR $GMAB Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 36.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,978,058 shares of the company’s stock after buying an additional 1,334,919 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.77% of Genmab A/S worth $153,324,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. Founders Capital Management lifted its holdings in shares of Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after buying an additional 400 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Genmab A/S by 11.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after buying an additional 419 shares during the period. CWM LLC increased its stake in Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after purchasing an additional 433 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Genmab A/S by 29.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after purchasing an additional 440 shares in the last quarter. Finally, Osaic Holdings Inc. increased its stake in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Stock Down 2.0%

Shares of NASDAQ GMAB opened at $24.58 on Tuesday. Genmab A/S Sponsored ADR has a 1 year low of $20.23 and a 1 year high of $35.43. The firm has a market cap of $15.33 billion, a price-to-earnings ratio of 18.62, a PEG ratio of 1.49 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The stock’s 50-day simple moving average is $26.71 and its 200-day simple moving average is $29.18.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GMAB shares. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Morgan Stanley assumed coverage on Genmab A/S in a research report on Monday, February 16th. They set an “equal weight” rating and a $34.00 price target for the company. Wolfe Research assumed coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price target for the company. Finally, Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.